Table 3.
Hazard ratios for OS, LC and PFS in cervical cancer
| Factors | Pts | OS | multivariate analysis | LC | multivariate analysis | PFS | multivariate analysis | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4-y OS (%) | P-value | HR (95%CI) | P-value | 4-y LC (%) | P-value | HR (95%CI) | P-value | 4-y PFS (%) | P-value | HR (95%CI) | P-value | |||
| FIGO stage (2008) | ||||||||||||||
| IB2-II | 264 (56.3%) | 84.8 | 0.085 | 90.4 | 0.094 | 67.3 | 0.058 | |||||||
| III-IVA | 205 (43.7%) | 78.3 | 85.3 | 60.0 | ||||||||||
| Pelvic LN metastasis | ||||||||||||||
| Yes | 253 (53.9%) | 80.6 | 0.125 | 88.9 | 0.571 | 62.4 | 0.111 | |||||||
| No | 216 (46.1%) | 83.8 | 87.4 | 66.3 | ||||||||||
| Histological subtype | ||||||||||||||
| Scc | 438 (93.4%) | 82.8 | 0.056 | 89.2 | 0.007* | 3.55 (1.66-7.60) | 0.001* | 65.1 | 0.119 | |||||
| Non-Scc | 31 (6.6%) | 72.1 | 73.6 | 50.9 | ||||||||||
| Uterine body inv. | ||||||||||||||
| Yes | 182 (38.8%) | 75.2 | 0.002* | 0.53 (0.35-0.79) | 0.002* | 82.5 | 0.024* | 52.7 | 0.001* | 0.57 (0.42-0.76) | <0.001* | |||
| No | 286 (61%) | 86.4 | 91.8 | 71.4 | ||||||||||
| N/A | 1 (0.2%) | |||||||||||||
| Pyometra | ||||||||||||||
| Yes | 118 (25.2%) | 80.9 | 0.719 | 69.7 | 0.566 | 57.4 | 0.309 | |||||||
| No | 351 (74.8%) | 82.4 | 74.1 | 66.4 | ||||||||||
| Parametrium inv. | ||||||||||||||
| Yes | 66 (14.1%) | 82.2 | 0.070 | 71.5 | 0.209 | 63.1 | 0.252 | |||||||
| No | 403 (85.9%) | 87.4 | 81.2 | 70.7 | ||||||||||
| Hydronephrosis | ||||||||||||||
| Yes | 96 (20.5%) | 84.3 | 0.654 | 74.4 | 0.663 | 61.2 | 0.554 | |||||||
| No | 373 (79.5%) | 81.5 | 72.6 | 64.9 | ||||||||||
| Tumor size at diagnosis | ||||||||||||||
| <7 cm | 386 (82.3%) | 83.5 | 0.095 | 89.5 | 0.096 | 66.3 | 0.029* | |||||||
| ≥7 cm | 83 (17.7%) | 75.5 | 82.7 | 54.5 | ||||||||||
| Tumor size before BT | ||||||||||||||
| <4 cm | 249 (53.1%) | 86.8 | 0.014* | 91.3 | 0.021* | 67.0 | 0.129 | |||||||
| ≥4 cm | 220 (46.9%) | 76.7 | 84.7 | 61.0 | ||||||||||
| HR-CTV D90 | ||||||||||||||
| HR-CTV D90 > 65Gy | 275 (58.6%) | 81.4 | 0.229 | 90.5 | 0.080 | 64.5 | 0.707 | |||||||
| HR-CTV D90 ≤ 65Gy | 194 (41.4%) | 83.1 | 85.0 | 63.8 | ||||||||||
| HR-CTV D95 | ||||||||||||||
| HR-CTV D95 > 60Gy | 269 (57.4%) | 80.9 | 0.099 | 90.3 | 0.020* | 2.14 (1.25-3.64) | 0.005* | 63.9 | 0.076 | |||||
| HR-CTV D95 ≤ 60Gy | 181 (38.6%) | 82.1 | 83.7 | 62.0 | ||||||||||
| Unknown | 19 (4%) | |||||||||||||
| Reduction ratio | ||||||||||||||
| ≤29% | 234 (49.9%) | 74.5 | <0.001* | 2.02 (1.33-3.07) | 0.001* | 84.0 | 0.004* | 2.49 (1.41-4.38) | 0.002* | 58.2 | 0.010* | 1.49 (1.1-2.0) | 0.010* | |
| >29% | 235 (50.1%) | 89.6 | 92.4 | 70.2 | ||||||||||
| Total Treatment Time | ||||||||||||||
| <9wks | 447 (95.3%) | 82.1 | 0.943 | 88.9 | 0.021* | 0.33 (0.17-0.93) | 0.033* | 65.2 | 0.021* | 0.56 (0.32-0.98) | 0.042* | |||
| ≥9wks | 22 (4.7%) | 81.0 | 73.5 | 43.8 | ||||||||||
| Type of BT | ||||||||||||||
| ICBT | 280 (59.7%) | 85.3 | 0.004* | 1.51 (1.00-2.27) | 0.049* | 89.3 | 0.314 | 68.4 | 0.014* | |||||
| HBT | 189 (40.3%) | 77.0 | 86.8 | 57.8 | ||||||||||
FIGO: the International Federation of Gynecology and Obstetrics
LN: lymph node
BT: brachytherapy
HR-CTV: high-risk clinical target volume
ICBT: intracavitary brachytherapy
HBT: hybrid brachytherapy
OS: overall survival
LC: local control
PFS: progression-free survival
*Statistical significance was defined as a P-value of <0.05.